Dr. Kai Pinkernell, M.D. joins Glycostem s leadership team as Chief Medical Officer
OSS, Netherlands, April 1, 2021 /PRNewswire/
Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that Dr. Kai Pinkernell, M.D. joins Glycostem as Chief Medical Officer (CMO). With a strong background in pharmaceutical clinical development and medical affairs management, Dr. Kai Pinkernell will lead the next steps in the clinical development strategy of Glycostem s lead product oNKord (NK) and viveNK
TM (CAR-NK), cell therapies for treatment of hematologic malignancies and solid tumors.
Dr. Pinkernell has more than 20 years of experience in the development of cell and gene therapies and 15 years of senior management experience, including clinical development strategies and their execution at globally operating biotechnology companies. In addition, Dr. Pinkernell has expertise
Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Russia s Second Coronavirus Vaccine Triggers Antibodies, Studies Say After Controversy
themoscowtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themoscowtimes.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / Cytovia Therapeutics Opens Boston R&D Center of Excellence and Announces cGMP Manufacturing Facility, Aiming to Start Clinical Trials for its Gene-Edited iPSC CAR-NK Cells by 2022
Cytovia Therapeutics Opens Boston R&D Center of Excellence and Announces cGMP Manufacturing Facility, Aiming to Start Clinical Trials for its Gene-Edited iPSC CAR-NK Cells by 2022
R&D labs for NK cell biology, gene-editing, antibody and CAR development, and NK cell pilot manufacturing opens in Natick, MA
Cell therapy manufacturing facility with best-in-industry clinical and commercial capacity to open in Aguadilla, Puerto Rico
CAMBRIDGE, Mass. and AVENTURA, Fla., March 17, 2021 (GLOBE NEWSWIRE) Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK-Engager Bispecific antibodies, announced today two agreements for R&D and manufactur